In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5

The present study was aimed to further characterize the pharmacological profile of N-[4-(trifluoromethyl) benzyl]-4-methoxybutyramide (GET73), a putative negative allosteric modulator (NAM) of metabotropic glutamate subtype 5 receptor (mGluR5) under development as a novel medication for the treatment of alcohol dependence. This aim has been accomplished by means of a series of in vitro functional assays. These assays include the measure of several down-stream signaling [intracellular Ca++ levels, inositol phosphate (IP) formation and CREB phosphorylation (pCREB)] which are generally affected by mGluR5 ligands. In particular, GET73 (0.1 nM–10 μM) was explored for its ability to displace the concentration-response curve of some mGluR5 agonists/probes (glutamate, L-quisqualate, CHPG) in different native preparations. GET73 produced a rightward shift of concentration-response curves of glutamate- and CHPG-induced intracellular Ca++ levels in primary cultures of rat cortical astrocytes. The compound also induced a rightward shift of concentration response curve of glutamate- and L-quisqualate-induced increase in IP turnover in rat hippocampus slices, along with a reduction of CHPG (10 mM)-induced increase in IP formation. Moreover, GET73 produced a rightward shift of concentration-response curve of glutamate-, CHPG- and L-quisqualate-induced pCREB levels in rat cerebral cortex neurons. Although the engagement of other targets cannot be definitively ruled out, these data support the view that GET73 acts as an mGluR5 NAM and support the significance of further investigating the possible mechanism of action of the compound.

[1]  L. Leggio,et al.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers☆ , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  L. Leggio,et al.  Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters , 2017, Data in brief.

[3]  B. Mason.  Emerging pharmacotherapies for alcohol use disorder , 2017, Neuropharmacology.

[4]  M. Soyka,et al.  Pharmacotherapy of alcoholism – an update on approved and off-label medications , 2017, Expert opinion on pharmacotherapy.

[5]  Hannah C. Saternos,et al.  Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder , 2017, Neuroscience & Biobehavioral Reviews.

[6]  M. Morgan,et al.  Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore , 2017, Alimentary pharmacology & therapeutics.

[7]  T. Kenakin.  Signaling bias in drug discovery , 2017, Expert opinion on drug discovery.

[8]  L. Ferraro,et al.  GET73 Prevents Ethanol-Induced Neurotoxicity in Primary Cultures of Rat Hippocampal Neurons. , 2016, Alcohol and alcoholism.

[9]  G. Hasler,et al.  Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window , 2016, The international journal of neuropsychopharmacology.

[10]  J. Macor,et al.  Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5. , 2016, ACS medicinal chemistry letters.

[11]  Brittney S. Bates,et al.  VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[12]  P Jeffrey Conn,et al.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation , 2015, Molecular Pharmacology.

[13]  Kari A. Johnson,et al.  Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents , 2015, Neuron.

[14]  M. Soyka,et al.  Recent Developments in Pharmacotherapy of Alcoholism , 2015, Pharmacopsychiatry.

[15]  R. Swift,et al.  Pharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies , 2015, Harvard review of psychiatry.

[16]  S. Laporte,et al.  Allosteric and Biased G Protein-Coupled Receptor Signaling Regulation: Potentials for New Therapeutics , 2014, Front. Endocrinol..

[17]  Y. Izumi,et al.  Intracellular mGluR5 Can Mediate Synaptic Plasticity in the Hippocampus , 2014, The Journal of Neuroscience.

[18]  R. Bruggeman,et al.  Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter? , 2014, ISRN psychiatry.

[19]  L. Ferraro,et al.  GET73 increases rat extracellular hippocampal CA1 GABA levels through a possible involvement of local mGlu5 receptor , 2013, Synapse.

[20]  J. Krystal,et al.  Glutamatergic targets for new alcohol medications , 2013, Psychopharmacology.

[21]  L. Ferraro,et al.  The new compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its "anti-alcohol" and anxiolytic properties. , 2013, Current medicinal chemistry.

[22]  Andrew S. Felts,et al.  Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships , 2012, Molecular Pharmacology.

[23]  G. Colombo,et al.  Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73 , 2012, Front. Psychiatry.

[24]  A. Lawrence,et al.  The role of metabotropic glutamate receptors in addiction: Evidence from preclinical models , 2012, Pharmacology Biochemistry and Behavior.

[25]  B. Sarah,et al.  GET73 modulates rat hippocampal glutamate transmission: evidence for a functional interaction with mGluR5. , 2011 .

[26]  C. Langmead,et al.  Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.

[27]  L. Leggio,et al.  Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. , 2011, Current pharmaceutical design.

[28]  P Jeffrey Conn,et al.  Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity , 2010, Molecular Pharmacology.

[29]  S. Ozaki,et al.  Regulation of spontaneous Ca2+ spikes by metabotropic glutamate receptors in primary cultures of rat cortical neurons , 2010, Journal of neuroscience research.

[30]  G. Addolorato,et al.  Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. , 2010, Current pharmaceutical design.

[31]  R. Spanagel.  Alcoholism: a systems approach from molecular physiology to addictive behavior. , 2009, Physiological reviews.

[32]  Margaret I Davis,et al.  Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity , 2009, Glia.

[33]  L. Mao,et al.  Regulation of mitogen‐activated protein kinases by glutamate receptors , 2007, Journal of neurochemistry.

[34]  P. Conn,et al.  Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[35]  Jens-Uwe Peters,et al.  Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[36]  L. Mao,et al.  Phosphorylation of cAMP response element‐binding protein in cultured striatal neurons by metabotropic glutamate receptor subtype 5 , 2003, Journal of neurochemistry.

[37]  L. Mao,et al.  Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors. , 2002, Molecular pharmacology.

[38]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[39]  G. Collingridge,et al.  (RS)-2-Chloro-5-Hydroxyphenylglycine (CHPG) Activates mGlu5, but not mGlu1, Receptors Expressed in CHO Cells and Potentiates NMDA Responses in the Hippocampus , 1997, Neuropharmacology.

[40]  L. Ferraro,et al.  Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: Interaction between NMDA and EAA metabotropic receptors , 1994, Neurochemistry International.

[41]  L. Ferraro,et al.  Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. , 2015, Journal of Alzheimer's disease : JAD.

[42]  M. Olive.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction. , 2009, Current drug abuse reviews.

[43]  T. Kenakin.  Allosteric Drug Antagonism , 2009 .

[44]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[45]  Oliver Mf.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction. , 2009 .